目次

1. Introduction to Oncolytic Virus: Trail From Genesis To Biogenetics

2. Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses Towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.3 Viral Oncolysis Mechanism of Action

3. Oncolytic Viruses Immunotherapy Overview
3.1 Stimulation of Antitumor Immune Responses
3.2 Oncolytic Viruses as Cancer Vaccines

4. Potential Oncolytic Virus Immunotherapy for Cancers
4.1 Breast Cancer
4.2 Lung Cancer
4.3 Prostate Cancer
4.4 Melanoma
4.5 Brain Tumor
4.6 Blood Cancer
4.7 Colorectal Cancer
4.8 Bladder Cancer
4.9 Pancreatic Cancer
4.10 Head and Neck Cancer

5. Global Oncolytic Virus Immunotherapy Therapy Market Overview
5.1 Preface Towards Oncolytic Virus Arcade
5.2 Market Aspects of Approved Oncolytic Viruses

6. Imlygic (Talimogene laherparepvec): Clinical and Pricing Insight
6.1 Clinical Overview
6.2 Availability, Dosage and Price Analysis

7. Oncorine (H101): Clinical and Pricing Insight
7.1 Clinical Overview
7.2 Availability, Dosage and Price Analysis

8. Delytact (DS 1647): ): Clinical and Pricing Insight
8.1 Clinical Overview
8.2 Availability, Dosage and Price Analysis

9. Global Oncolytic Virus Immunotherapy Clinical Pipeline Overview
9.1 By Phase
9.2 By Company
9.3 By Country
9.4 By Indication
9.5 By Patient Segment

10. Global Oncolytic Viruses Clinical Pipeline By Company, Indication and Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III
10.7 Registered

11. Strategic Partnerships, Collaborations, Mergers and Acquisitions to Advance the Oncolytic Virus Therapy Market
11.1 Estrella Biopharma Signs Deal To Merge With Blank Check Company
11.2 ABL and Imugene Announce Partnership to Advance Oncolytic Virus Candidates Into Late Clinical Trial Phase
11.3 TILT Biotherapeutics and Merck to Undergo Clinical Trial Collaboration for Refractory Non-Small Cell Lung Cancer
11.4 Virogin Biotech and MD Anderson Announce Strategic Collaboration For Treating Advance Cancers
11.5 ABL Signs Pact With KaliVir On Oncolytic Viruses
11.6 Targovax Announces Clinical Collaboration With Agenus For Melanoma Trial
11.7 KaliVir Announces Exclusive Agreement With Roche For Developing Novel Oncolytic Viruses
11.8 ImmVira and Roche Enter Cooperation Agreement For Evaluating Novel Combination For Cancer Therapy
11.9 Calidi and Edoc Agree On Merger To Revolutionize Oncolytic Viral Therapies
11.10 Synthetic Biologics Completes Acquisition of VCN Biosciences
11.11 VacV Biotherapeutics Exits Stealth With $3 Million Investment
11.12 Targovax Enters Research Collaboration With Karolinska Institutet Professor
11.13 Transgene and PersonGen To Collaborate To Evaluate New Combination Therapy Against Solid Tumors
11.14 Lokon Pharma Initiates Collaboration With To Develop Novel Cancer Therapeutics
11.15 Bionaut Labs and Candel Therapeutics Announce Collaboration For Novel Targeting Mechanism For Oncolytic Virus Delivery
11.16 Imugene and Eureka Announce Strategic Collaboration to Accelerate Oncolytic Virus and T-Cell Therapy Combination
11.17 CG Oncology Enters Into Clinical Trial Collaboration With Roche For Novel Oncolytic Immunotherapy Combination
11.18 Imugene Enters Into Exclusive Strategic Partnership With Celularity To Develop Novel Combination For Treating Solid Tumors

12. Global Oncolytic Virus Immunotherapy Market Dynamics
12.1 Favorable Market Parameters
12.2 Growth Inhibitors

13. Global Oncolytic Virus Immunotherapy Market Future Outlook

14. Competitive Landscape
14.1 AdCure Bio
14.2 Beijing SyngenTech
14.3 BioVex Inc.
14.4 Calidi Biotherapeutics
14.5 Genelux Corporation
14.6 Immvira Pharma
14.7 Jennerex Biotherapeutics
14.8 KaliVir
14.9 Lokon Pharma
14.10 Merck
14.11 Oncolys BioPharma
14.12 Oncorus
14.13 PsiOxus Therapeutics
14.14 Seneca Therapeutics
14.15 Shanghai Sunway Biotech
14.16 Takara Bio
14.17 Targovax
14.18 TILT Biotherapeutics
14.19 Transgene
14.20 Virogin Biotech

List of Figures & Tables
Figure 1-1: Demonstration of Categorization of Oncolytic Viruses
Figure 1-2: Illustration of Major Events in Clinical Virotherapy
Figure 2-1: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 2-2: The Diagrammatic Representation of Entry of Virions into Cancerous cells
Figure 2-3: Route of Anti-tumoral Efficacy of Oncolytic Viruses
Figure 2-4: Mechanism of Tumor Destruction by Oncolytic Viruses
Figure 2-5: Categorization Followed by Oncolytic Viruses for Tumor Selectivity
Figure 3-1: Demonstration of Phases of Immune Responses Elicited by the Oncolytic Viruses
Figure 3 2: Categorization of Oncolytic Viruses over the Basis of their Behavior
Figure 3 3: Diagrammatic Representation of Oncolysis Shown by Reovirus
Figure 3 4: Mechanism of Oncolytic Behavior of Adenoviruses
Figure 4-1: Selectively Killing of Prostate Cancer Cells by Oncolytic M-Protein Strains of VSV
Figure 4-2: Proposed Treatment of Oncolytic Viruses for Hematological Malignancies
Figure 5-1: Global - Oncolytic Virus Immunotherapy Market Opportunity (US$ Million), 2021 -2028
Figure 6-1: Imlygic - US Patent Expiration Year
Figure 6-2: Imlygic - Price of 1 Million PUF/ml and 100 Million PUF/ml Injectable Suspension (US$), November’2022
Figure 6-3: Imlygic - Dose for Initial Treatment Cycle and Subsequent Treatment Cycle (Million PFU/ ml), November’2022
Figure 6-4: Imlygic - Duration of Initial and Subsequent Treatment Cycle (weeks), November’2022
Figure 6-5: Imlygic - Average Price of Initial Treatment Cycle and Each Subsequent Treatment Cycle (US$), November’2022
Figure 6-6: Imlygic - Volume Administered by Size of Lesion (ml), November’2022
Figure 7-1: Oncorine - Cost of Single Dose and Single Treatment Course (US$), September’2020
Figure 7-2: Oncorine - Duration of Treatment Cycle by Type of Cancer (Days), November’2022
Figure 8-1: Delytact - Initial and Present Price (US$), November’2022
Figure 8-2: Delytact - Designations
Figure 8-3: Japan - Malignant Gliomas Incidences, 2022-2026
Figure 9-1: Oncolytic Virus Immunotherapy Clinical Trials by Phase (Numbers), 2022 till 2028
Figure 9-2: Global - Oncolytic Virus Immunotherapy Clinical Trials by Company (Numbers), 2022 till 2028
Figure 9-3: Global - Oncolytic Virus Immunotherapy Clinical Trials by Country (Numbers), 2022 till 2028
Figure 9-4: Global - Oncolytic Virus Immunotherapy Clinical Trials by Indication (Numbers), 2022 till 2028
Figure 9-5: Global - Oncolytic Virus Immunotherapy Clinical Trials by Patient Segment (Numbers), 2022 till 2028
Figure 12-1: Major Drivers for the Oncolytic Virus Therapies
Figure 12-2: Major Challenges Faced by Oncolytic Viral Therapies